# A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection

> **NCT04856761** · — · UNKNOWN · sponsor: **Fudan University** · enrollment: 160 (estimated)

## Conditions studied

- Biliary Tract Neoplasms
- Recurrence
- Cholangiocarcinoma
- Gall Bladder Cancer

## Interventions

- **DRUG:** S-1
- **DRUG:** Capecitabine

## Key facts

- **NCT ID:** NCT04856761
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11-01
- **Primary completion:** 2022-12-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2022-08-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04856761

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04856761, "A Study of Capecitabine Versus S-1 as Adjuvant Therapy in Patients With Biliary Tract Carcinoma After Surgical Resection". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04856761. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*